Search

Ipsen SA.

Gesloten

SectorFinanciƫn

119.9

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

119.6

Max

121.8

Belangrijke statistieken

By Trading Economics

Inkomsten

334M

Verkoop

1.8B

K/W

Sectorgemiddelde

22.045

25.743

Dividendrendement

1.17

Winstmarge

18.354

Werknemers

5,358

EBITDA

637M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+7.44% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

1.17%

3.67%

Volgende Winsten

12 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

9.8B

Vorige openingsprijs

119.9

Vorige sluitingsprijs

119.9

Nieuwssentiment

By Acuity

43%

57%

160 / 525 Rangschikking in Finance

Technische score

By Trading Central

Vertrouwen

Strong Bullish Evidence

Ipsen SA. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 jan 2026, 21:14 UTC

Belangrijke Marktbewegers

Ventyx Biosciences Gains on Report of Possible $1 Billion Eli Lilly Deal

6 jan 2026, 19:23 UTC

Acquisities, Fusies, Overnames

OneStream to Go Private Through $6.4 Billion Hg Acquisition

6 jan 2026, 17:41 UTC

Belangrijke Marktbewegers

Blink Charging Shares Rise as EV Chargers Begin Accepting Cryptocurrency

6 jan 2026, 15:46 UTC

Acquisities, Fusies, Overnames

Advent International Leads InPost Takeover Offer, Sky News Says

6 jan 2026, 15:37 UTC

Belangrijke Marktbewegers

Terrestrial Energy Shares Rise After DOE Agreement For Nuclear Plant Development

6 jan 2026, 23:46 UTC

Marktinformatie

Nikkei May Decline After Hitting Record High -- Market Talk

6 jan 2026, 23:35 UTC

Marktinformatie

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

6 jan 2026, 23:19 UTC

Marktinformatie

Greatland 2Q Gold Output Strong, Sales Soft -- Market Talk

6 jan 2026, 22:53 UTC

Marktinformatie

WiseTech, REA and CAR Look Best Insulated From AI Threat -- Market Talk

6 jan 2026, 22:03 UTC

Acquisities, Fusies, Overnames

Staar Surgical: Merger Proposal Received 14.9M Votes For and 27.3M Against

6 jan 2026, 22:03 UTC

Acquisities, Fusies, Overnames

Staar Surgical, Which Earlier Reported Stockholder Rejection of Sale to Alcon, Reports Vote Totals

6 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

6 jan 2026, 21:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

6 jan 2026, 21:12 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

6 jan 2026, 21:12 UTC

Marktinformatie

Commodity Demand Helps Canada Reduce Reliance on Trade With U.S. -- Market Talk

6 jan 2026, 20:59 UTC

Belangrijke Marktbewegers
Acquisities, Fusies, Overnames

Ventyx Biosciences Gains on Report of Possible $1B Eli Lilly Deal

6 jan 2026, 20:40 UTC

Acquisities, Fusies, Overnames

Acquisition of Ventyx Would Bring Lilly Into Emerging Category of Pills for Inflammation-Related Conditions -- WSJ

6 jan 2026, 20:40 UTC

Acquisities, Fusies, Overnames

Eli Lilly Nears Deal for Biotech Ventyx -- WSJ

6 jan 2026, 20:40 UTC

Acquisities, Fusies, Overnames

Deal Could Be Announced Imminently, Sources Say -- WSJ

6 jan 2026, 20:40 UTC

Acquisities, Fusies, Overnames

Eli Lilly in Advanced Talks to Buy Ventyx Biosciences For Over $1B, Sources Say -- WSJ

6 jan 2026, 20:01 UTC

Marktinformatie

Oil Futures Give Back Post-Venezuela Incursion Gains -- Market Talk

6 jan 2026, 19:52 UTC

Marktinformatie

U.S. Natural Gas Falls Awaiting Colder Weather -- Market Talk

6 jan 2026, 19:46 UTC

Acquisities, Fusies, Overnames

Under Armour Stock Rises After the 'Warren Buffet of Canada' Boosts Its Stake -- Barrons.com

6 jan 2026, 19:08 UTC

Acquisities, Fusies, Overnames

OneStream to Go Private Through $6.4B Hg Acquisition

6 jan 2026, 18:28 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Sandisk, Nvidia, AMD, Palantir, OneStream, SoFi, Microchip, and More -- Barrons.com

6 jan 2026, 17:20 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

6 jan 2026, 17:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

6 jan 2026, 15:57 UTC

Marktinformatie

Crude Futures Ease Back From Early Gains -- Market Talk

6 jan 2026, 15:34 UTC

Marktinformatie
Winsten

Bank of Montreal Expects to Exit 2027 With ROE Hitting 15% Target -- Market Talk

6 jan 2026, 15:27 UTC

Marktinformatie

German Inflation Won't Fall Much Further in 2026 -- Market Talk

Ipsen SA. Prognose

Koersdoel

By TipRanks

7.44% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 130Ā EURĀ  7.44%

Hoogste 145Ā EUR

Laagste 120Ā EUR

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ipsen SA. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

1

Buy

2

Hold

0

Sell

Technische score

By Trading Central

99.85 / 104Steun & Weerstand

Korte Termijn

Strong Bullish Evidence

Gemiddeld Termijn

Strong Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Sentiment

By Acuity

160 / 525 Rangschikking in Financiƫn

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
help-icon Live chat